Menopause care after cancer.
Non-hormonal. Coordinated. Compassionate.

Why this matters

Cancer treatment frequently triggers menopause — sometimes abruptly through chemotherapy, ovarian suppression, bilateral oophorectomy, or endocrine therapy. Symptoms are typically more severe than natural menopause because the drop in estradiol is precipitous rather than gradual: overnight the ovaries stop producing hormones the brain has depended on for decades. Hot flashes, sleep disruption, cognitive fog, joint pain, mood shifts, and genitourinary changes often arrive simultaneously.

Systemic estrogen — the standard first-line therapy for vasomotor symptoms — is typically off the table after estrogen-receptor-positive (ER+) breast cancer, endometrial cancer, and certain ovarian cancers. That does not mean nothing can help. In 2026, evidence-based non-hormonal options have never been stronger.

Non-hormonal options Kindr providers prescribe

• Fezolinetant (Veozah), 45 mg/day. Non-hormonal NK3 receptor antagonist; FDA-approved 2023 for moderate-to-severe vasomotor symptoms. ~55–65% reduction vs. placebo (SKYLIGHT 1/2). Requires baseline and periodic ALT/AST monitoring.
• Elinzanetant (Lynkuet). Dual NK1/NK3 antagonist, FDA-approved 2025. Additional benefit for sleep and mood — often the best-tolerated single-agent option for survivors.
• Venlafaxine 37.5–75 mg, escitalopram 10–20 mg, desvenlafaxine 100 mg. First-line SSRI/SNRIs for hot flashes in breast cancer survivors — supported by the MsFLASH network trials. Venlafaxine is preferred alongside tamoxifen (minimal CYP2D6 inhibition).
• Paroxetine 7.5 mg (Brisdelle). Only SSRI FDA-approved specifically for hot flashes. Avoid with tamoxifen — strong CYP2D6 inhibition reduces active metabolite (endoxifen).
• Gabapentin 300–900 mg at bedtime. Particularly useful when night sweats and insomnia dominate the picture.
• Oxybutynin 2.5–5 mg twice daily. ~60% reduction; short-term use preferred given anticholinergic burden.
• Vaginal moisturizers, hyaluronic acid suppositories, ospemifene 60 mg, DHEA (prasterone) intravaginal. For genitourinary syndrome of menopause when local estrogen is not appropriate.
• CBT for insomnia (CBT-I) and CBT for hot flashes. First-line non-pharmacologic; MENOS trial shows ~50% reduction in symptom bother.
• Clinical hypnosis. 50–74% reduction in randomized trials (Elkins, J Clin Oncol 2013). Underused option.

Bone health after cancer

Aromatase inhibitors, GnRH agonists, and chemotherapy-induced menopause all accelerate bone loss. Baseline DEXA scan, adequate calcium (1,200 mg/day total) and vitamin D (800–2,000 IU targeting 25-OH-D >30 ng/mL), weight-bearing and resistance exercise, and — when indicated — bisphosphonates or denosumab. Kindr providers order the baseline labs and coordinate osteoporosis pharmacotherapy with your oncology team.

Cardiovascular and metabolic surveillance

Early menopause raises long-term cardiovascular risk. We track lipid panel, ApoB, fasting glucose or HbA1c, and blood pressure annually, and address modifiable risk actively — because the WHI "healthy user" window that protects natural menopause is not available to most survivors. GLP-1 therapies are appropriate for weight management when clinically indicated and cleared with your oncologist.

Coordination with your oncology team

Kindr providers will request that you stay connected to your oncology team, particularly if you are on tamoxifen, an aromatase inhibitor, ovarian suppression, or other adjuvant therapy. We share our treatment plan with your oncologist, respect prescribing preferences, and route decisions back through them when there is any question of interaction — paroxetine reducing tamoxifen efficacy is only the most well-known example. This is complementary care, not competing care.

Vaginal estrogen: a nuanced conversation

Low-dose vaginal estrogen (estradiol tablets, cream, or ring) delivers minimal systemic absorption and is considered acceptable by NAMS and ACOG for many breast cancer survivors when non-hormonal options have failed — after a documented conversation with the treating oncologist. Aromatase inhibitors complicate this decision because they aim for near-zero circulating estradiol. Kindr does not make this call unilaterally; we make it with your oncologist.

What we will not do

Kindr will not prescribe systemic estrogen to women with a history of ER+ breast cancer or other estrogen-sensitive malignancies. We do not use unregulated compounded "bioidentical" pellets. We do not sell products marketed as replacing oncology follow-up.

Related

Fezolinetant · Elinzanetant · Paroxetine · Hot flashes · Bone health · Mental wellness

Sources

NAMS 2023 Nonhormone Therapy Position Statement · ASCO Survivorship Guidelines 2023 · SKYLIGHT 1/2 (Lancet 2023) · OASIS 1/2 elinzanetant (JAMA 2024) · MsFLASH network (JAMA Intern Med, JCO) · MENOS trial (Lancet Oncol 2012) · Elkins hypnosis RCT (J Clin Oncol 2013) · Faubion et al., Menopause 2018 (vaginal estrogen in survivors).